HormoneInvestigational

Hexarelin

Subcutaneous injection, Intravenous

Overview

A synthetic hexapeptide growth hormone secretagogue with the highest GH-releasing potency among GHRPs. Hexarelin binds both GHS-R1a and CD36 (scavenger receptor), giving it unique cardiovascular properties independent of GH release.

Mechanism of Action

It exhibits cardioprotective effects through reduced atherosclerotic plaque formation and improved cardiac contractility via direct myocardial receptor activation..

Research Summary & Key Findings

Clinical trials demonstrated the most potent acute GH release among GHRPs. Unique CD36-mediated cardiovascular effects include improved cardiac output in heart failure patients and reduced lipid accumulation in macrophages. Subject to significant tachyphylaxis with chronic dosing, limiting long-term utility for GH augmentation (Broglio et al., J Endocrinol Invest, 2005).

Clinical Status

Investigational

Hexarelin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Subcutaneous injectionIntravenous

Related Peptides in Hormone

Find a Provider

Find a verified provider who offers Hexarelin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Hexarelin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.